Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
Aasha I. Hoogland(Moffitt Cancer Center), Heather Jim(Moffitt Cancer Center), Yvelise Rodriguez(Moffitt Cancer Center), Farhad Khimani(Moffitt Cancer Center), Kelly A. Hyland(University of South Florida), Margaret Booth‐Jones(Moffitt Cancer Center), Frederick L. Locke(Moffitt Cancer Center), Bijal Shah(Boston College), Anna Barata(Massachusetts General Hospital), Reena Jayani(Vanderbilt University Medical Center), Nathaly Irizarry‐Arroyo(Moffitt Cancer Center), Gabriel Krivenko(Moffitt Cancer Center), Muneer H. Abidi(Spectrum Health), Hien Liu(Moffitt Cancer Center), Aaron Collier(Moffitt Cancer Center), Taiga Nishihori(Moffitt Cancer Center), Christina A. Bachmeier(Moffitt Cancer Center), Julio C. Chávez(Moffitt Cancer Center), Javier Pinilla‐Ibarz(Moffitt Cancer Center), Michael D. Jain(Moffitt Cancer Center), Brian W. James(University of South Florida), Aleksandr Lazaryan(Moffitt Cancer Center)
Cited by 35
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k